Next-Generation Blood Culture Analysis System

Publication ID: 24-11857320_0005_PTD
Published: November 07, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Blood Culture Analysis System,” Published Technical Disclosure No. 24-11857320_0005_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857320_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,320.

Summary of the Inventive Concept

A revolutionary system integrating blood sequestration devices with real-time analysis capabilities, enabling rapid diagnosis and targeted treatment of microbial infections.

Background and Problem Solved

The original patent's blood sequestration device, while effective, has limitations in terms of speed and accuracy of diagnosis. The present inventive concept addresses these limitations by incorporating advanced microfluidic and machine learning technologies to provide real-time blood culture analysis, enabling caregivers to respond promptly to microbial infections.

Detailed Description of the Inventive Concept

The next-generation blood culture analysis system comprises a microfluidic chip integrated with a blood sequestration device, which collects a blood sample and analyzes it in real-time using machine learning-based algorithms to identify microbial infections. The system can be configured as a wearable device, transmitting samples to a remote analysis center for diagnosis. Alternatively, the system can be implemented as a network of interconnected blood sequestration devices, providing a comprehensive view of a patient's blood health across multiple sampling sites. The system's advanced analytics enable personalized treatment recommendations based on a patient's genomic profile.

Novelty and Inventive Step

The integration of microfluidic and machine learning technologies with blood sequestration devices represents a significant departure from the original patent, providing a paradigm shift in blood culture analysis. The inventive concept's real-time analysis capabilities, wearable and networked configurations, and personalized treatment recommendations constitute novel and non-obvious advancements.

Alternative Embodiments and Variations

Alternative embodiments may include handheld or portable devices, implantable sensors, or cloud-based analysis platforms. Variations may involve different microfluidic chip designs, machine learning algorithms, or genomic profiling techniques.

Potential Commercial Applications and Market

The next-generation blood culture analysis system has vast commercial potential in the healthcare industry, particularly in hospitals, clinics, and remote patient monitoring settings. The system's ability to provide rapid and accurate diagnoses can significantly reduce healthcare costs and improve patient outcomes, making it an attractive solution for healthcare providers and patients alike.

Original Patent Information

Patent NumberUS 11,857,320
TitleBlood sequestration device and method
Assignee(s)Smiths Medical ASD, Inc.